Stories tagged “Pharmaceuticals.”
30 stories
Analysis reveals that only individuals with nearly £100,000 in discretionary income annually can offset the £1,200 cost of GLP-1 weight-loss drugs through reduced food spending, effectively making the medication a "regressive tax on being thin" for most users.
Insmed reported total revenues of $425.5 million, driven by a $309.2 million contribution from the commercial launch of BRINSUPRI. The company raised its fiscal 2026 revenue guidance for BRINSUPRI and increased its long-term combined peak sales estimate for three lead ass…
African companies investing in France: South African pharma Aspen [1/5]
South African pharmaceutical giant Aspen has invested over 200 million euros in France, making its Norman factory a key European production site for injectable anticoagulants and syringes. This investment challenges the perception of African companies primarily seeking ai…
Fresenius, a German healthcare company, has raised its full-year earnings forecast after a strong second quarter. The company's core earnings per share are expected to rise by 10 to 15 percent compared to last year, up from a previous forecast of 5 to 10 percent.
Novo Nordisk, a Danish pharmaceutical company, has reported a higher-than-expected quarterly profit and raised its earnings and sales projections for the year. The company's profit for the second quarter was 33.4 billion Danish kroner, up 11% from the previous year.
AstraZeneca's chief executive, Pascal Soriot, is considering a $400bn US mega-merger with Bristol Myers Squibb, but experts question the logic behind this move.
Britain's AstraZeneca is in discussions to acquire its US rival Bristol Myers Squibb in a potential $400bn deal, which would create one of the world's largest pharmaceutical companies.
The 27th Iran Health International Exhibition will be held from August 8 to 11 at the Tehran Permanent International Fairground, showcasing the latest technological achievements in the healthcare sector.
The article compares the State Street Health Care Select Sector SPDR ETF (XLV) and the Invesco Nasdaq Biotechnology ETF (IBBQ), discussing their differences in terms of cost, size, and performance.
Bristol Myers Squibb looks attractive from a value perspective, but the company is facing a material patent cliff that investors need to monitor. The patent protections for new drugs are time-limited, and research and development outcomes are unpredictable.
Pharmaceutical company Amgen suffered a data breach after threat actors stole corporate data and patient information stored in multiple cloud systems operated by third-party service providers.
Pharmaceutical company GSK is moving over 1,000 scientists to its new £400m research and development centre in Cambridge, a vote of confidence in British business. The move is accompanied by encouraging news for shareholders, including a plan to cut £1.9bn of annual costs…
Buckley Capital Advisors highlighted Liquidia Corporation (NASDAQ: LQDA) in its second-quarter 2026 investor letter, citing 50%+ upside on Yutrepia ruling and buyout potential.
Johnson & Johnson has offered $5.5 billion to settle tens of thousands of lawsuits claiming its baby powder and other talcum powder products caused ovarian cancer.
Iran and India discussed ways to deepen health ties, including cooperation in traditional medicine, pharmaceuticals, and vaccine supply chains. Indonesia also expressed interest in Iran's expertise in health sectors, including organ transplantation and medicine manufactur…
Australia's Therapeutic Goods Administration (TGA) has warned about a rare but severe eye disorder, non-arteritic anterior ischaemic optic neuropathy (NAION), linked to GLP-1 drugs like Ozempic, Wegovy, and Mounjaro. The condition can lead to permanent vision loss.
Investors seeking healthcare exposure must choose between targeted pharmaceutical plays and diversified global baskets. The VanEck Pharmaceutical ETF (PPH) provides concentrated exposure to global drugmakers, while the iShares Global Healthcare ETF (IXJ) offers broader ac…
Indian drugmakers rattled by Trump’s 100% levy on generics
U.S. President Donald Trump's plan to impose steep tariffs on generic medicines has unsettled Indian drugmakers and put the spotlight on their strategy in their biggest export market.
The U.S. FDA has issued a nationwide alert to recall four production lots of a generic antihistamine due to the risk of Ranitidine contamination. Consumers are advised to inspect their medicine cabinets for affected products and discontinue use if found.
US President Donald Trump has announced a new policy to impose tariffs on generic drugs imported into the US, starting from August 2026. This move is expected to have a significant impact on the Indian pharmaceutical industry, which supplies a substantial portion of gener…
U.S. President Donald Trump plans to impose high tariffs on generic drugs imported into the U.S. starting in 2028 to push generic drugmakers to move production onshore. The phased schedule will see zero tariffs for two years, followed by a 100% levy and then 200% a year l…
Novo Nordisk sues Eli Lilly over 'materially misleading' ads for its weight-loss and anti-diabetes treatments, accusing the US company of using outdated trial data to make its products appear more effective.
Broad Pharmaceutical Group Shifts Focus to Women's Health, Seeking to Capitalize on the 'She Economy'
Broad Pharmaceutical Group, a leading Chinese pharmaceutical company, is shifting its focus to women's health, seeking to capitalize on the growing 'she economy'. The company has established a new platform, Broad Beauty, to develop and market beauty and personal care prod…
China’s private sector has seen a significant leap in pharmaceutical innovation, with domestically produced novel drugs accounting for 80% of market approvals in the first half of the year.
Vertex Pharmaceuticals has acquired Crinetics Pharmaceuticals for $10 billion, gaining access to products for endocrine diseases and a pipeline of promising candidates. This move diversifies Vertex's portfolio and could drive strong financial results.
Stoke Therapeutics' lead asset, zorevunersen, for Dravet Syndrome has fully enrolled its Phase 3 EMPEROR trial, with top-line results anticipated in H2 2027.
Investors comparing the iShares U.S. Pharmaceuticals ETF (IHE) and the iShares Global Healthcare ETF (IXJ) must choose between concentrated U.S. pharmaceutical industry exposure and a broader, global healthcare strategy.
The article discusses three high-yield dividend stocks: Pfizer, Novo Nordisk, and Sanofi. These companies have faced challenges but are worth investing in for the long haul, especially for dividend seekers.
Xenon Pharmaceuticals is transitioning into a late-stage, cash-rich neuroscience company with a validated Kv7 potassium channel platform and strong Phase 3 epilepsy data. XENE's lead candidate, azetukalner, showed robust efficacy in refractory focal onset seizures and is …
Chinese drugmakers with big ambitions struggle to recruit staff for global expansion
Chinese drugmakers with global ambitions are struggling to recruit internationally experienced staff needed to develop and commercialize promising medicines overseas. The shortage reflects how China's rapid rise as a hub for testing experimental, next-generation medicines…